Psilostachyin C: a natural compound with trypanocidal activity.
Valeria P Sülsen1, Fernanda M Frank, Silvia I Cazorla
1Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 (1113), Buenos Aires, Argentina.
International Journal of Antimicrobial Agents
|April 19, 2011
Summary
Psilostachyin C, a natural compound, shows potent antiprotozoal activity against Trypanosoma cruzi and Leishmania species. This sesquiterpene lactone demonstrates efficacy in vitro and in vivo, offering a promising lead for new drug development.
Area of Science:
- Natural Product Chemistry
- Parasitology
- Medicinal Chemistry
Background:
- Protozoan infections like Chagas disease remain a significant global health concern.
- There is a continuous need for novel therapeutic agents with improved efficacy and safety profiles.
- Natural products offer a rich source of diverse chemical structures for drug discovery.
Purpose of the Study:
- To investigate the antiprotozoal activity of the sesquiterpene lactone psilostachyin C.
- To evaluate the efficacy of psilostachyin C against Trypanosoma cruzi and Leishmania species.
- To assess the safety profile of psilostachyin C in mammalian cells.
Main Methods:
- Isolation of psilostachyin C from Ambrosia scabra via bioassay-guided fractionation.
- Identification of the compound using spectroscopic techniques.
- In vitro assays to determine inhibitory concentrations (IC50) against various parasite stages and cytotoxicity (CC50) against mammalian cells.
- In vivo studies in infected mice to assess therapeutic efficacy.
- Transmission electron microscopy to observe ultrastructural changes in parasites.
Main Results:
- Psilostachyin C exhibited potent in vitro trypanocidal activity against Trypanosoma cruzi (IC50 values ranging from 0.6 to 3.5 μg/mL) with low cytotoxicity to mammalian cells (CC50 = 87.5 μg/mL).
- The compound induced significant ultrastructural alterations in T. cruzi parasites.
- In vivo treatment of infected mice with psilostachyin C led to a significant reduction in parasite load.
- Psilostachyin C also demonstrated inhibitory activity against Leishmania mexicana and Leishmania amazonensis promastigotes (IC50 = 1.2 and 1.5 μg/mL, respectively).
Conclusions:
- Psilostachyin C is a promising natural compound with significant antiprotozoal activity against Trypanosoma cruzi and Leishmania species.
- Its favorable efficacy and safety profile suggest potential as a lead compound for developing novel trypanocidal and leishmanicidal agents.
- Further research into its mechanism of action and optimization is warranted for therapeutic development.
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...